Table 1.
Summary of results and clinicopathological characteristics of GI-NEN cases examined in this study
| Patient characteristics of neuroendocrine tumor | |
| Total number | 70 |
| Sex, male/female | 42/28 |
| Median age in years (range) | 60 (33–82) |
| Grade (WHO 2019) | NET-G1, n = 49; NET-G2, n = 19; NET-G3, n = 2 |
| Primary lesion of NET | Foregut, n = 33; Hindgut, n = 37 |
| Case of lymph node metastasis in NET G1 | Metastatic (pathologically), n = 5; Not detected (clinically), n = 20;Not detected (pathologically), n = 10; Unclarified, n = 14 |
| MGMT score | Score0, n = 1; Score1, n = 15; Score2, n = 15; Score3, n = 39 |
| GLUT2 score | Score0, n = 21; Score1, n = 10; Score2, n = 18; Score4, n = 18; Score6, n = 3 |
| MGMT methylation specific PCR | Negative, n = 35; Positive, n = 0; Not examined, n = 35 |
| Median Ki-67 labeling indexa (range) | 1.89 (0.33–48.3) |
| Patient characteristics of neuroendocrine carcinoma | |
| Total number | 14 |
| Sex, male/female | 10/4 |
| Median age in years (range) | 70 (60–86) |
| Primary lesion of NEC | Foregut, n = 10; Hindgut, n = 4 |
| MGMT score | Score0, n = 1; Score1, n = 0; Score2, n = 4; Score3, n = 9 |
| MGMT methylation specific PCR | Negative, n = 12; Positive, n = 2 |
aRound the fourth digit